SPIKENET: An Evidence-Based Therapy for Long COVID
Elumalai N, Hussain H, Sampath N, Shamaladevi N, Hajjar R, Druyan B, Rashed A, Ramamoorthy R, Kenyon N, Jayakumar A, Paidas M. SPIKENET: An Evidence-Based Therapy for Long COVID. Viruses 2024, 16: 838. PMID: 38932130, PMCID: PMC11209161, DOI: 10.3390/v16060838.Peer-Reviewed Original ResearchCarcinoembryonic antigen-related cell adhesion molecule 1Murine hepatitis virus-1Post-acute sequelae of COVID-19SARS-CoV-2 variantsSARS-CoV-2Development of severe inflammationCell adhesion molecule 1Long-term complicationsAdhesion molecule 1Multiple organ damagePotential therapeutic benefitMultiple SARS-CoV-2 variantsEvidence-based therapiesSequelae of COVID-19ACE2 receptor-binding domainSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Severe inflammationTissue edemaOrgan damageRespiratory syndrome coronavirus 2Long COVIDMolecule 1Receptor-binding domainSyndrome coronavirus 2